NHS Framework for the North of England, Branded Medicine

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Framework (Products)
Duration
2 year
Value
£432M
Sector
HEALTH
Published
01 Mar 2022
Delivery
01 Mar 2022 to 29 Feb 2024
Deadline
20 Oct 2021 13:00

Concepts

Location

Geochart for 1 buyers and 31 suppliers

1 buyer

31 suppliers

Description

Offer reference number: CM/PHR/20/5600 CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Award Detail

1 Thornton & Ross (Huddersfield)
  • Value: £238,913,892
2 Janssen Cilag (High Wycombe)
  • Value: £238,913,892
3 Biogen (Maidenhead)
  • Value: £238,913,892
4 Merck Serono (Feltham)
  • Value: £238,913,892
5 Celltrion Healthcare (Slough)
  • Value: £238,913,892
6 Bristol Myers Squibb (Uxbridge)
  • Value: £238,913,892
7 Astrazeneca (Luton)
  • Value: £238,913,892
8 Ul Global Pharma (None)
  • Value: £238,913,892
9 Glaxosmithkline (London)
  • Value: £238,913,892
10 Roche Products (Garden City)
  • Value: £238,913,892
11 Bayer (Reading)
  • Value: £238,913,892
12 Merck Sharpe & Dohme (London)
  • Value: £238,913,892
13 Pfizer (None)
  • Value: £238,913,892
14 Accord (None)
  • Value: £238,913,892
15 Novo Nordisk (Gatwick)
  • Value: £238,913,892
16 Sandoz (Camberley)
  • Value: £238,913,892
17 Napp Pharmaceuticals (Cambridge)
  • Value: £238,913,892
18 Eli Lilly (Basingstoke)
  • Value: £238,913,892
19 Ipsen (Slough)
  • Value: £238,913,892
20 Amgen (Cambridge)
  • Value: £238,913,892
21 Aventis Pharma (Reading)
  • Value: £238,913,892
22 Ucb Pharma (Slough)
  • Value: £238,913,892
23 Teva (Castleford)
  • Value: £238,913,892
24 Zentiva Pharma (London)
  • Value: £238,913,892
25 CST Pharma (Walsall)
  • Value: £238,913,892
26 Takeda (London)
  • Value: £238,913,892
27 Mylan (Barnet)
  • Value: £238,913,892
28 Gilead Sciences (Holborn)
  • Value: £238,913,892
29 Organon Pharmaceuticals (London)
  • Value: £238,913,892
30 Gedeon Richter (None)
  • Value: £238,913,892
31 Sobi Swedish Orphan Biovitrum (None)
  • Value: £238,913,892

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Reference

Domains